Phaseline

Companies › Keros Therapeutics

Keros Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Neurology; next expected readout Aug 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
KER-065
Activin type IIB receptor (ActR2B) ligand trap; inhibits myostatin and ActA signaling
ACVR2BPhase 2Duchenne Muscular DystrophyAug 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07704099KER-065Phase 2Duchenne Muscular DystrophyNeurologyAug 2028

From the company's SEC filings

Cash of $259m on 2026-09-30; operating cash outflow about $28m a year; runway about 113 months at that burn, to Feb 2036; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Agreements filed with the SEC (item 1.01), last two years

Specialist investors

Held by 3 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

ACVR2B (1)

Companies with the same targets

Eli Lilly

Companies built like this

Abcuro Tiziana Life Sciences Acumen Pharmaceuticals Bright Minds Biosciences Dianthus Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.